Inogen Inc. logo

Inogen Inc. (INGN)

Market Closed
17 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
6. 57
-0.09
-1.3514%
$
171.38M Market Cap
- P/E Ratio
- Div Yield
134,900 Volume
-3.4 Eps
$ 6.66
Previous Close
Add Transaction
Day Range
6.54 6.66
Year Range
5.34 9.13
Want to track INGN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Inogen (INGN) Reports Q1 Loss, Tops Revenue Estimates

Inogen (INGN) Reports Q1 Loss, Tops Revenue Estimates

Inogen (INGN) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.62 per share a year ago.

Zacks | 1 year ago
Here's Why You Should Retain Inogen Stock in Your Portfolio Now

Here's Why You Should Retain Inogen Stock in Your Portfolio Now

Expanding product portfolio and high prospects for POC raise optimism for INGN stock.

Zacks | 1 year ago
Inogen (INGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Inogen (INGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks | 1 year ago
Here's Why You Should Retain Inogen Stock in Your Portfolio Now

Here's Why You Should Retain Inogen Stock in Your Portfolio Now

Inogen, Inc.  INGN is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid fourth-quarter 2024 performance and a strong product portfolio, seems justified.

Zacks | 1 year ago
A Volatile Share Price Masks Some Of The Progress At Inogen

A Volatile Share Price Masks Some Of The Progress At Inogen

Inogen's new management and strategy are yielding results, with better-than-expected 2024 performance and a more stable base from which to keep growing the B2B business. Despite weak DTC sales, strong B2B growth drove better-than-expected sales in Q4, and Inogen likewise beat on margins. Guidance disappointed investors and prompted a 15% drop in the shares, as moderately better revenue guidance was offset by unexpected gross margin deleverage.

Seekingalpha | 1 year ago
What's Going On With MedTech Focused Inogen Stock On Wednesday?

What's Going On With MedTech Focused Inogen Stock On Wednesday?

Medical Technology company Inogen Inc INGN reported a fourth-quarter adjusted EPS loss of 24 cents, compared to a loss of 83 cents a year ago, beating the consensus loss of 61 cents.

Benzinga | 1 year ago
INGN Stock Gains Following Q4 Earnings Beat, Adjusted Gross Margin Up

INGN Stock Gains Following Q4 Earnings Beat, Adjusted Gross Margin Up

Inogen's overall fourth-quarter 2024 results continue to gain from higher business-to-business sales.

Zacks | 1 year ago
Inogen, Inc. (INGN) Q4 2024 Earnings Call Transcript

Inogen, Inc. (INGN) Q4 2024 Earnings Call Transcript

Inogen, Inc. (NASDAQ:INGN ) Q4 2024 Earnings Conference Call February 25, 2025 5:00 PM ET Company Participants Ryan Peterson – Investor Relations Kevin Smith – President and Chief Executive Officer Mike Bourque – Chief Financial Officer Conference Call Participants Operator Welcome to Inogen's Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Seekingalpha | 1 year ago
Inogen (INGN) Reports Q4 Loss, Tops Revenue Estimates

Inogen (INGN) Reports Q4 Loss, Tops Revenue Estimates

Inogen (INGN) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $1.14 per share a year ago.

Zacks | 1 year ago
Here's Why You Should Add Inogen Stock to Your Portfolio Now

Here's Why You Should Add Inogen Stock to Your Portfolio Now

Expanding product portfolio and high prospects for POC raise optimism for INGN stock.

Zacks | 1 year ago
Inogen Stock May Gain on Deal With Yuwell to Expand Global Reach

Inogen Stock May Gain on Deal With Yuwell to Expand Global Reach

INGN and Yuwell collaborate to expand and enhance Inogen's innovation pipeline through R&D collaboration and accelerate the entry of Inogen's brand into the Chinese market.

Zacks | 1 year ago
Inogen (INGN) Moves to Strong Buy: Rationale Behind the Upgrade

Inogen (INGN) Moves to Strong Buy: Rationale Behind the Upgrade

Inogen (INGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks | 1 year ago
Loading...
Load More